Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics today and set a price target of $80.00. Tsao covers the He...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$95.35	+3.36%	1.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTGX	$95.35	+3.4%	1.29M
3
4
5
6

PTGX

PTGX

Dividend Overview

Get Protagonist Therapeutics Inc. Data in Excel

Get Protagonist Therapeutics Inc. Data in Excel